Equities

RaQualia Pharma Inc

4579:TYO

RaQualia Pharma Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)599.00
  • Today's Change-5.00 / -0.83%
  • Shares traded53.90k
  • 1 Year change-25.22%
  • Beta1.1647
Data delayed at least 20 minutes, as of May 02 2024 07:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

RaQualia Pharma Inc. is a Japan-based company engaged in the research and development of pharmaceutical products. The Company is mainly engaged in the discovery and research, the preclinical trials and part of clinical trials of drugs, as well as the licensing of developed compounds to pharmaceutical companies. The Company is focused on pain diseases area and intestinal disease area. Its products include EP4 antagonist, cyclooxygenase-2 (COX-2) inhibitory, 5-HT4 portion partial agonist, among others.

  • Revenue in JPY (TTM)1.90bn
  • Net income in JPY-323.66m
  • Incorporated2008
  • Employees67.00
  • Location
    RaQualia Pharma Inc8F, Daiwa Meieki Bldg.1-21-19, Meieki-MinamiNakamura-kuNAGOYA-SHI 450-0003JapanJPN
  • Phone+81 524466100
  • Fax+81 525650700
  • Websitehttps://www.raqualia.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
4579:TYO since
announced
Transaction
value
FIMECS IncDeal completed14 Feb 202414 Feb 2024Deal completed-5.22%29.84m
Data delayed at least 20 minutes, as of May 02 2024 07:00 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Stella Pharma Corp254.09m-765.17m9.43bn46.00--3.53--37.11-25.23-25.238.3285.550.06370.04563.585,523,718.00-19.18---20.37--82.76---301.14--11.90-1,173.120.2671--128.85---1.45------
3-D Matrix Ltd3.74bn-1.06bn9.47bn108.00--15.49--2.53-14.90-14.9054.067.740.66530.46545.1934,630,130.00-18.91-57.69-23.28-77.3164.0440.76-28.43-205.342.33--0.8717--53.6358.87-29.09---7.69--
Linical Co Ltd12.52bn680.40m10.12bn759.0013.581.188.510.808330.1230.12554.28346.380.7251--3.9916,494,230.003.944.716.557.2333.1031.605.435.98--17,809.030.279345.368.326.5527.06-4.97-33.014.94
TMS Co Ltd0.00-960.04m10.32bn14.00--2.98-----25.89-25.890.0085.770.00-------26.14---26.78-----------------------11.51------
AnGes Inc152.99m-7.44bn10.67bn145.00--0.3726--69.72-39.40-39.400.8083131.520.00450.10378.401,055,069.00-21.97-28.50-25.69-33.1412.7139.42-4,861.66-6,726.821.75--0.0137--128.13-24.1749.45--12.11--
KOEI CHEMICAL COMPANY, LIMITED18.49bn62.58m11.00bn387.00175.470.50593.740.59512.7912.793,779.784,437.990.45991.304.5147,770,930.000.15573.760.2064.6824.9124.120.33856.660.53561.770.308935.807.550.4997-26.56-33.8215.6820.11
Medinet Co Ltd724.63m-1.41bn11.47bn98.00--1.97--15.82-6.31-6.313.2322.880.122411.933.617,394,143.00-23.74-21.05-24.75-22.4717.7228.75-193.90-135.4019.58--0.00--4.40-7.90-14.66---17.67--
Veritas In Silico Inc360.36m33.05m12.13bn15.00356.567.48202.2133.665.245.2457.19250.05------24,023,730.00------------9.17--20.19--0.00--101.54--123.38------
ReproCell Inc2.51bn-217.49m12.31bn92.00--1.53--4.91-2.56-2.5629.4890.900.30084.867.4427,247,390.00-2.61-9.37-2.80-10.1143.5538.78-8.68-38.1211.94--0.00--32.1626.1046.91--28.24--
Nano Mrna Co Ltd164.39m-1.05bn12.60bn17.00--3.62--76.65-14.94-14.942.3449.400.029518.962.609,669,765.00-18.85-25.13-23.29-26.0480.6784.69-638.22-538.318.95--0.2418---23.42-4.8430.33------
RaQualia Pharma Inc1.90bn-323.66m12.96bn67.00--2.12--6.82-14.99-14.9987.98283.050.28963.133.1528,376,150.00-4.932.13-5.292.2687.1188.49-17.025.3212.35--0.05670.00-34.8520.62-144.74--0.0967--
Healios KK121.00m-3.82bn13.43bn64.00--2.88--110.99-55.07-55.071.7851.710.008--0.39291,890,625.00-25.27-23.55-35.99-28.5283.47---3,152.89-6,580.16---13.680.6756--34.44--26.04---22.00--
Ohki Healthcare Holdings Co Ltd327.51bn2.35bn14.28bn576.005.990.53285.380.0436170.32170.3223,747.191,914.312.3711.644.27568,593,700.001.651.957.989.115.207.120.69620.75390.8536--0.1913.289.454.91124.49-1.16-1.279.46
Oncolys Biopharma Inc63.04m-1.94bn14.80bn34.00--9.40--234.76-108.23-108.233.5475.100.02692.190.30011,854,059.00-82.64-45.75-97.13-51.8648.5560.46-3,075.14-233.665.15--0.1761---93.54-17.86-68.72--28.18--
Microwave Chemical Co Ltd1.89bn98.88m15.15bn59.00217.948.8786.078.014.454.45116.78109.320.65269.376.5332,055,120.003.41--4.65--54.51--5.23--2.6511.240.2309--41.24--168.39------
Data as of May 02 2024. Currency figures normalised to RaQualia Pharma Inc's reporting currency: Japanese Yen JPY

Institutional shareholders

3.36%Per cent of shares held by top holders
HolderShares% Held
Heights Capital Management, Inc.as of 05 Jan 2023625.00k2.89%
Simplex Asset Management Co., Ltd.as of 04 Apr 202482.20k0.38%
SSgA Funds Management, Inc.as of 04 Apr 202418.10k0.08%
DFA Australia Ltd.as of 31 May 20231.72k0.01%
Dimensional Fund Advisors Ltd.as of 30 Nov 20230.000.00%
Dimensional Fund Advisors LPas of 31 Dec 20230.000.00%
More ▼
Data from 31 Dec 2023 - 25 Apr 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.